Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease
Aim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol in achieving target heart rate (HR) in patients with ischemic heart disease.Material and methods. Patients with ischemic heart disease (n=60; 36 males and 24 females) aged from 35 to 75 years were includ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2016-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1194 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227723660066816 |
|---|---|
| author | E. I. Tarlovskaya T. I. Chudinovskikh |
| author_facet | E. I. Tarlovskaya T. I. Chudinovskikh |
| author_sort | E. I. Tarlovskaya |
| collection | DOAJ |
| description | Aim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol in achieving target heart rate (HR) in patients with ischemic heart disease.Material and methods. Patients with ischemic heart disease (n=60; 36 males and 24 females) aged from 35 to 75 years were included into the study. Patients were randomized into group A (received therapy based on the original bisoprolol) or into group B (received therapy based on of generic bisoprolol). Ivabradine was added, if the effect was insufficient. The duration of follow-up was 6 weeks. The HR dynamics was assessed during the study period. Cost/effectiveness ratio was calculated.Results. Significant HR slowing was found in both groups by the end of observation. In group A baseline HR was 70.0±5.6 beats/min and in 6 weeks - 58.1±3.8 beats/min, while in group B - 69.5±5.2 and 60.5±3.9 beats/min respectively. HR slowing was significantly higher in group A than that in group B. Direct costs in order to achieve a target HR in 1 patient for 6 weeks of therapy in group A were 663.75 rubles, while this in group B - 1093.58 rubles. Direct costs for HR deceleration by 1 beat in group A were 48.46 rubles vs 69.40 rubles in group B. The effect of therapy based on the original bisoprolol, is superior to that when generic bisoprolol used.Conclusion. HR-slowing effect of therapy based on the original bisoprolol was superior to that when generic bisoprolol was used. Pharmacoeconomic analysis revealed that HR deceleration was more economically profitable in treatment based on the original bisoprolol. |
| format | Article |
| id | doaj-art-55eb5eacb3de416482f110ae8c1080b9 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2016-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-55eb5eacb3de416482f110ae8c1080b92025-08-23T10:00:26ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-03-01121404410.20996/1819-6446-2016-12-1-40-441180Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart diseaseE. I. Tarlovskaya0T. I. Chudinovskikh1Nizhny Novgorod State Medical Academy. Minina and Pozharskogo pl., 10/1, Nizhny Novgorod, 603005 RussiaKirov State Medical Academy. K. Marxa ul. 112, Kirov, 610027 Russian FederationAim. To compare the efficacy and cost/effectiveness ratio of the original and generic bisoprolol in achieving target heart rate (HR) in patients with ischemic heart disease.Material and methods. Patients with ischemic heart disease (n=60; 36 males and 24 females) aged from 35 to 75 years were included into the study. Patients were randomized into group A (received therapy based on the original bisoprolol) or into group B (received therapy based on of generic bisoprolol). Ivabradine was added, if the effect was insufficient. The duration of follow-up was 6 weeks. The HR dynamics was assessed during the study period. Cost/effectiveness ratio was calculated.Results. Significant HR slowing was found in both groups by the end of observation. In group A baseline HR was 70.0±5.6 beats/min and in 6 weeks - 58.1±3.8 beats/min, while in group B - 69.5±5.2 and 60.5±3.9 beats/min respectively. HR slowing was significantly higher in group A than that in group B. Direct costs in order to achieve a target HR in 1 patient for 6 weeks of therapy in group A were 663.75 rubles, while this in group B - 1093.58 rubles. Direct costs for HR deceleration by 1 beat in group A were 48.46 rubles vs 69.40 rubles in group B. The effect of therapy based on the original bisoprolol, is superior to that when generic bisoprolol used.Conclusion. HR-slowing effect of therapy based on the original bisoprolol was superior to that when generic bisoprolol was used. Pharmacoeconomic analysis revealed that HR deceleration was more economically profitable in treatment based on the original bisoprolol.https://www.rpcardio.online/jour/article/view/1194beta-blockersgenericpharmacoeconomicsheart rate slowing therapyischemic heart disease |
| spellingShingle | E. I. Tarlovskaya T. I. Chudinovskikh Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease Рациональная фармакотерапия в кардиологии beta-blockers generic pharmacoeconomics heart rate slowing therapy ischemic heart disease |
| title | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| title_full | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| title_fullStr | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| title_full_unstemmed | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| title_short | Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| title_sort | pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease |
| topic | beta-blockers generic pharmacoeconomics heart rate slowing therapy ischemic heart disease |
| url | https://www.rpcardio.online/jour/article/view/1194 |
| work_keys_str_mv | AT eitarlovskaya pharmacoeconomicanalysisofheartrateslowingdrugsinpatientswithischemicheartdisease AT tichudinovskikh pharmacoeconomicanalysisofheartrateslowingdrugsinpatientswithischemicheartdisease |